Evidence map›Paper›PMID 37584289›Full record

ArticleHaematologica2024

Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study.

Pierre-Edouard Debureaux, Nathalie Forgeard, Dikelele Elessa, Stéphanie Harel, Laurent Frenzel, Bruno Royer, Alexis Talbot, Sylvain Choquet, Frederic Davi, Florence Nguyen-Khac and 10 more

Open access · goldAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Pierre-Edouard DebureauxINSERM U1160 EMiLy, Institut de Recherche Saint-Louis, Université Paris-Cité, Paris, France; Department of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris. Pierre-edouard.debureaux@aphp.fr.
Nathalie ForgeardDepartment of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris, France; Sorbonne Université, Department of Hematology, Hospital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Paris.
Dikelele ElessaDepartment of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris.
Stéphanie HarelDepartment of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris.
Laurent FrenzelDepartment of Hematology, Hospital Necker, Assistance Publique Hopitaux de Paris, Paris.
Bruno RoyerDepartment of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris.
Alexis TalbotDepartment of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris.
Sylvain ChoquetSorbonne Université, Department of Hematology, Hospital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Paris.
Frederic DaviLaboratory of Hematology, Hospital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Paris.
Florence Nguyen-KhacLaboratory of Hematology, Hospital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France; Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS1138, Drug Resistance in Hematological Malignancies Team, Paris.
Wendy CuccuiniLaboratory of Cytogenetic, Hospital Saint Louis, Assistance Publique Hopitaux de Paris, Paris.
Morgane CheminantDepartment of Hematology, Hospital Necker, Assistance Publique Hopitaux de Paris, Paris.
Clotilde BravettiLaboratory of Hematology, Hospital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Paris.
Gregory LazarianLaboratory of Hematology, Hospital Avicenne, Assistance Publique Hopitaux de Paris, Paris.
Sophie KaltenbachLaboratory of Hematology, Hospital Necker, Assistance Publique Hopitaux de Paris, Paris.
Olivier HermineDepartment of Hematology, Hospital Necker, Assistance Publique Hopitaux de Paris, Paris.
Damien Roos-WeilSorbonne Université, Department of Hematology, Hospital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Paris.
Marion EspéliINSERM U1160 EMiLy, Institut de Recherche Saint-Louis, Université Paris-Cité, Paris.
Karl BalabanianINSERM U1160 EMiLy, Institut de Recherche Saint-Louis, Université Paris-Cité, Paris.
Bertrand ArnulfDepartment of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris, France; University of Paris Cité, Paris. Bertrand.arnulf@aphp.fr.
Assistance Publique – Hôpitaux de Paris · FRHôpital Saint-Louis · FRUniversité Paris Cité · FRCentre de Recherche des Cordeliers · FRHôpital Avicenne · FRInserm · FRInstitut de recherche Saint-Louis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Waldenstrom MacroglobulinemiaAgammaglobulinaemia Tyrosine KinaseHumansInflammationProtein Kinase InhibitorsTyrosine Kinase InhibitorsAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Identifiers

PMID37584289
PMCPMC10772506
OpenAlexW4385851248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.